1621 / 1708
Clinical Investigation: Pediatrics
Quality of Survival and Growth in Children and Young
Adults in the PNET4 European Controlled Trial of
Hyperfractionated Versus Conventional Radiation Therapy
for Standard-Risk Medulloblastoma
Colin Kennedy, MBBS, MD
, *Kim Bull, PhD
, *Mathilde Chevignard, MD,
y
,
z
David Culliford, MSc
, *Helmuth G. Do¨ rr, MD,
x
Franc¸ois Doz, MD,
k
Rolf-Dieter Kortmann, MD,
{
Birgitta Lannering, MD
, #Maura Massimino, MD
, **Aurora Navajas Gutie´ rrez, MD,
yy
Stefan Rutkowski, MD,
zz
Helen A. Spoudeas, MD,
xx
and Gabriele Calaminus, MD,
kk
, on behalf of the, PNET4 study group of the Brain
Tumour Group of The European branch of the International Society of Paediatric
Oncology (SIOP-E)
*University of Southampton Faculty of Medicine and University Hospital Southampton National Health Service
Foundation Trust, Southampton, United Kingdom;
y
Hoˆpitaux de Saint Maurice, Saint Maurice, France;
z
Neurophysiology,
University of Pierre et Marie-Curie Paris 6, Paris, France;
x
Kinder- und Jugendklinik der Universita¨t Erlangen, Erlangen,
Germany;
k
Institut Curie and University Paris Descartes, Sorbonne Paris Cite´, France;
{
Department of Radiation Therapy,
University of Leipzig, Leipzig, Germany;
#
Department of Pediatrics, The Sahlgren Academy, University of Gothenburg,
Gothenburg, Sweden; **Fondazione Istituto di Ricovero e Cura a Carattere Scientifico IRCCS Istituto Nazionale dei
Tumori, Milan, Italy;
yy
Hospital Universitario Cruces, Baracaldo-Vizcaya, Spain;
zz
University Medical Center Hamburg-
Eppendorf, Hamburg, Germany;
xx
Center for Pediatric Endocrinology, University College London, London, United
Kingdom; and
kk
Pediatric Oncology, University of Muenster, Muenster, Germany
Received Jul 30, 2013, and in revised form Sep 25, 2013. Accepted for publication Sep 26, 2013.
Summary
We report on quality of sur-
vival in the PNET4 RCT
Purpose:
To compare quality of survival in “standard-risk” medulloblastoma after hyperfractionated
radiation therapy of the central nervous systemwith that after standard radiation therapy, combinedwith
a chemotherapy regimen common to both treatment arms, in the PNET4 randomised controlled trial.
Reprint requests to: Colin Kennedy, MBBS, MD, Mailpoint 803G,
University Child Health, Southampton General Hospital, Southampton,
SO16 6YD, United Kingdom. Tel: (
þ
44) (0) 2380-796678; E-mail:
crk1@ soton.ac.ukThis study was funded by The Brain Tumour Charity, the Children’s
Cancer and Leukaemia Group, Piam Brown Charitable Fund Southampton,
the German Ministry of Health and Education (BMBF 01GI9958/5), The
European Union’s Seventh Framework Programme (FP7 2007-2013) under
the project European Network of Cancercare in Children and Adolescents
(ENCCA) grant agreement no. 261743, the German Children’s Cancer
Foundation (Deutsche Kinderkrebsstiftung), the French Ministry of Health,
the French National Cancer Institute, the Swedish Childhood Cancer
Foundation, and Wessex Medical Research.
C.K. and K.B. are co-first authors.
Conflict of interest: none.
Supplementary material for this article can be found at
www.redjournal.org.
Acknowledgments
d
The authors thank the participating families;
Nathalie Algret, Luna Boschetti, Go¨ran Gustavsson, Carin Korbijn, Anders
Larsson, Roel Reddingius, and Carmen Teske; Barry Pizer and Roger
Taylor, who commented on earlier drafts of this article; the PNET4
committee; and all the PNET4 investigators.
Int J Radiation Oncol Biol Phys, Vol. 88, No. 2, pp. 292
e
300, 2014
0360-3016/$ - see front matter 2014 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.ijrobp.2013.09.046RadiationOncology
International Journal of
biology physics
www.redjournal.org